Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 7.18 Billion | USD 10.69 Billion | 4.2% | 2024 |
The global microsclerotherapy treatment market size was worth around USD 7.18 Billion in 2024 and is predicted to grow to around USD 10.69 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 4.2% between 2025 and 2034.
The report analyzes the global microsclerotherapy treatment market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the microsclerotherapy treatment industry.
Telangiectasia, a disorder where ruptured blood vessels close to the surface or mucous membrane appear as red or pink lines on the skin surface, is treated with microsclerotherapy. Both genetic and environmental factors influence Telangiectasia. Telangiectasia may also be brought on by aging, pregnancy, rosacea, excessive sun exposure, and varicose veins. Although there is no treatment for this illness, it can be managed using microsclerotherapy.
One of the primary driving factors influencing the growth of the worldwide microsclerotherapy market is the increasing prevalence of spider and varicose veins. The relatively painless treatment, low invasion, high effectiveness, fewer post-operative problems, and simple analgesia needed during the treatment are essential elements that propel the global market forward. Spider veins are more common in the elderly population.
Therefore, an increase in the geriatric population is yet another aspect that can positively impact the global market. Additionally, obesity, the prevalence of unhealthy lifestyles, and heredity throughout the projected period may impact the expansion of the worldwide microsclerotherapy market.
The increased cost of therapy, a lack of surgeon training, and other alternative methods are the major factors that may restrict the worldwide market growth.
The rise in the prevalence of varicose veins among women drives the market growth
One of the primary driving factors influencing the growth of the global microsclerotherapy treatment market is the increasing prevalence of spider and varicose veins. The global prevalence of varicose veins will rise dramatically in the next years. According to a survey by the Occupational Health & Safety Research Institute, the prevalence of varicose veins in the lower limbs varies between 10% and 30% worldwide.
The prevalence of varicose veins is much higher in women than in men. Pregnancy and repeated deliveries are the primary risk factors for spider veins in women due to increased expression of hormonal substances such as estrogen and progesterone. Varicose veins affect 55% of women and 45% of males.
The key factors further propelling the market's growth are relatively painless treatments, minimal invasion, high effectiveness, fewer post-operative side effects, and simple anesthesia required during the procedure.
High treatment costs and adverse treatment effects hinder the market growth
Adverse effects and expensive treatment costs are expected to hinder the global microsclerotherapy treatment market's expansion. Matting and persistent pigmentation have been observed as side effects of microsclerotherapy by 1–10% of patients, as per the Journal of Phelbolymphology. The treatments are costly, ranging from USD 600 - 1200, and the price is based on the size of the vein, with at least 2 to 6 treatment periods required at 4 to 6-week intervals. The process is a little difficult, and patients may find wearing a compression bandage for several weeks after surgery uncomfortable. Lack of training for surgeons is another factor that hinders market growth.
The global microsclerotherapy treatment market has been segmented into product type, end users, and region.
Based on product type, the sclerosants, sodium tetradecyl sulphate, polidocanol, chromated glycerin, hypertonic glucose, needles, and others are segments of the global microsclerotherapy treatment market. Among these, the sclerosants segment dominated the global market in 2021. Major manufacturers' commercialization and development of new sclerosants for the therapy of spider veins, such as polidocanol, sodium tetradecyl sulphate, and hypertonic saline, are accelerating segment expansion.
Based on end users, the market is classified into hospitals, aesthetic treatment clinics, and others. In 2021, the hospital category dominated the global market owing to a rise in the rate of hospitalization for spider veins and the wide variety of services given by hospitals in a centralized location.
Report Attributes | Report Details |
---|---|
Report Name | Microsclerotherapy Treatment Market |
Market Size in 2024 | USD 7.18 Billion |
Market Forecast in 2034 | USD 10.69 Billion |
Growth Rate | CAGR of 4.2% |
Number of Pages | 220 |
Key Companies Covered | Merz Pharma GmbH & Co. KGaA, Surgimedix Inc, Troikaa, QOL Medical LLC, McKesson Corporation, Kreussler Inc, Provensis, ltd, Omega Pharmaceuticals, STD Pharmaceuticals Product Ltd, Medtronic Plc, Endo-Flex, Boston Scientific Corporation, Teleflex Incorporated, and others. |
Segments Covered | By Product Type, By End Users, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, The Middle East and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2020 to 2023 |
Forecast Year | 2025 - 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America dominated the microsclerotherapy treatment market in 2034
Due to advanced healthcare facilities, an increasing emphasis on aesthetics, persistent lifestyle modifications, the prevalence of varicose veins, and a rise in disposable income, North America dominates the global microsclerotherapy treatment market. The presence of major players in the market and well-developed healthcare infrastructure in nations such as the U.S. and Canada are major factors driving the growth of the spider veins treatment industry in North America. Additionally, Americans can get this treatment at a reasonable cost because of the favorable reimbursement scenario. Furthermore, the existence of important players, early adoption of advanced technologies, and increased R&D activities are expected to propel the regional market.
The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the microsclerotherapy treatment market on a global and regional basis.
The global microsclerotherapy treatment market is dominated by players like:
By Product Type
By End Users
By Region
FrequentlyAsked Questions
Leading players in the global microsclerotherapy treatment market include Merz Pharma GmbH & Co. KGaA, Surgimedix Inc, Troikaa, QOL Medical LLC, McKesson Corporation, Kreussler Inc, Provensis, ltd, Omega Pharmaceuticals, STD Pharmaceuticals Product Ltd, Medtronic Plc, Endo-Flex, Boston Scientific Corporation, Teleflex Incorporated, among others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed